Thymus Neoplasms
10
3
4
3
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
10.0%
1 terminated out of 10 trials
75.0%
-11.5% vs benchmark
10%
1 trials in Phase 3/4
100%
3 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (10)
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.
Adjuvant Hypofractionation Radiotherapy for Thymic Epithelial Tumours After Complete Resection
Sunitinib for Advanced Thymus Cancer Following Earlier Treatment
Thoracic OncoGeriatric Assessment (TOGA) Trials
Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases
Study on Proton Radiotherapy of Thymic Malignancies
Esophageal Sparing Intensity-modulated Radiation Therapy (IMRT) for Locally-Advanced Thoracic Malignancies
Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma
18F FLT Imaging Studies of Treatment Response for Lung Cancer and Thymoma